



INFORMATION DISCLOSURE CITATION PTO-1449				ATTY. DOCKET NO. A-55320-2/RFT/MTK		SERIAL NO. 08/630,383	
				APPLICANT POULETTY et al.			
				FILING DATE April 10, 1996		GROUP 1816	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
ms	A	91/07418	30.05.91	WO	—	—	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
ms	B	Lussow, A.R., et al. "Targeting of Activated T-Cells with Natural Cytotoxic Antibodies via an IL2-Hapten Conjugate Prolongs Graft Survival", <i>Transplantation Proceedings</i> , Vol. 28, No. 2, pp.571-572 (April 1996).					
	C	Litton, M.J., et al., "Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma", <i>Eur. J. Immunol.</i> , Vol. 26, pp. 1-9 (1996).					
	D	Lussow, A.R., et al., "Redirecting Circulating Antibodies via Ligand-Hapten Conjugates Eliminates Target Cells in Vivo", <i>Journal of Immunotherapy</i> , Vol. 19(4), pp. 257-265 (1996).					
	E	Saha, B., et al., "Toxic Shock Syndrome Toxin-1-Induced Death is Prevented by CTLA4Ig ¹ ", <i>Journal of Immunology</i> , pp.3870-3875 (1996).					
	F	Kuge, S., et al. "Superantigen-Induced Human CD4 + Helper/Killer T Cell Phenomenon", <i>Journal of Immunology</i> , pp.1776-1785 (1995).					
	G	Lando, P.A., et al., "T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens", <i>Cancer Immunol Immunother</i> , Vol. 36, pp. 223-228 (1993).					
	H	Lussow, A.R., et al., "Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten conjugate Prolongs Cardiac Graft Survival ¹ ", <i>Transplantation</i> , Vol. 62, No. 12, pp. 1703-1708 (December 27, 1996).					
EXAMINER	ms			DATE CONSIDERED 1/23/2001			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 8085 1449A.FRM (8/95)

INFORMATION DISCLOSURE CITATION PTO-1449				ATTY. DOCKET NO. A-55320-2/RFT/TAL		SERIAL NO. 08/630,383		
				APPLICANT POULETTY et al.				
				FILING DATE April 10, 1996		GROUP 1644		
U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
M	1	0 180 171	5/1986	EP	-	-		
	2	0 352 761	7/1988	EP	-	-		
M	3	0 334 300	9/1989	EP	-	-		
M	4	90/11779	10/1990	PCT	-	-		
M	5	91/01004	1/1991	PCT	-	-		
M	6	88/03566	5/1988	PCT	-	-		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
M	7	Bacha et al., "Interleukin 2 Receptor-Targeted Cytotoxicity," J. Exp. Med., 167:612-622 (1988).						
M	8	Gravelle et al., "The Targeting of CD4+ T Lymphocytes to A B Cell Lymphoma," The Journal of Immunology, 142: 4079-4084 (1989).						
M	9	Staerz et al., "Hybrid antibodies can target sites for attack by T cells," Nature, 314:628-631 (1985).						
M	10	Staerz et al., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity," Proc. Natl. Acad. Sci. USA, 83:1453-1457 (1986).						
M	11	Murphy, J.R. "Diphtheria-related peptide hormone gene fusions: A molecular genetic approach to chimeric toxin," Immunotoxins, Frankel, A.E. (ed.), Kluwer Academic Publishers, 1988, 123-140.						
M	12	Martindale, The Extra Pharmacopeia, Reynolds, J. (ed.), The Pharmaceutical Press, 1989, p.1160.						
M	13	Alberts, B. (ed.), Molecular Biology of the Cell, Third Edition, Garland Publishing, 1994, 1169-1170.						
M	14	Oxford Dictionary of Biochemistry and Molecular Biology, Smith, A.D. (ed.), Oxford University Press, 1997, 155,216.						
EXAMINER				DATE CONSIDERED				
								

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 8085 1449A.FRM (8/95)
 1027958

CIPE JC98
SEP 08 2000
TRADEMARK

INFORMATION DISCLOSURE CITATION PTO-1449					ATTY. DOCKET NO. A-55320-2/RFT/TAL		SERIAL NO. 08/630,383	
					APPLICANT POULETTY et al.			
					FILING DATE April 10, 1996		GROUP 1644	
U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
mg	1	4,681,760	7/1987	Fathman	—	—		
MB	2	4,675,382	6/1987	Murphy	—	—		
MB	3	4,946,945	8/1990	Wojdani	—	—		
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
MB	4	2-169521	6/2/00	JP unexamined, published	—	—	x	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
km	5	Berkow et al., The Merck Manual, published by Merck Research Laboratories, 1992, p.353.						
MB	6	Tuevefson et al., Imm. Rev. 136:99-109 (1993).						
MB	7	Legaard et al., Cellular Immunology, 135:372-382 (1991).						
EXAMINER								
		DATE CONSIDERED 1/23/2001						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
8085 1449A.FRM (8/95)
1028847

INFORMATION DISCLOSURE
CITATION

DEC 05 2000

PTO-1449

ATTY. DOCKET NO.
A-55320-2/DJB/TAL
/DCF

SERIAL NO.
08/630,383

APPLICANT
POULETTY et al.

FILING DATE
April 10, 1996

GROUP
1644

U.S. PATENT DOCUMENTS

[illegible]

RECEIVED

DEC 11 2000

FOREIGN PATENT DOCUMENTS

~~TECH CENTER 1600/2900~~

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
<i>m</i>	1	93/17699	9/1993	PCT <i>wo</i>	—	—		
<i>ms</i>	2	95/34321	12/1995	PCT <i>wo</i>	—	—		
<i>pr</i>	3	96/35443	11/1996	PCT <i>wo</i>	—	—		
<i>pr</i>	4	97/24140	7/1997	PCT <i>wo</i>	—	—		
<i>pr</i>	5	97/37690	10/1997	PCT <i>wo</i>	—	—		
	6	4238416	5/1994	DE				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.